Karolinska Development Relationship 'No Longer Exclusive'
This article was originally published in Scrip
Karolinska Development AB and Karolinska Institutet Holding AB (the technology transfer company of the Karolinska Institute) have renegotiated their relationship into a new non-exclusive deal flow agreement. The move follows the appointment of new Karolinska Development chief executive Jim Van heusden earlier this year. He immediately began implementing a new strategy for the chronically underperforming Karolinska Development by positioning it as a venture capital company.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.